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Abstract
Background: The targeted capture and sequencing of genomic regions has rapidly demonstrated its utility in
genetic studies. Inherent in this technology is considerable heterogeneity of target coverage and this is expected to
systematically impact our sensitivity to detect genuine polymorphisms. To fully interpret the polymorphisms
identified in a genetic study it is often essential to both detect polymorphisms and to understand where and with
what probability real polymorphisms may have been missed.
Results: Using down-sampling of 30 deeply sequenced exomes and a set of gold-standard single nucleotide variant
(SNV) genotype calls for each sample, we developed an empirical model relating the read depth at a polymorphic site
to the probability of calling the correct genotype at that site. We find that measured sensitivity in SNV detection is
substantially worse than that predicted from the naive expectation of sampling from a binomial. This calibrated model
allows us to produce single nucleotide resolution SNV sensitivity estimates which can be merged to give summary
sensitivity measures for any arbitrary partition of the target sequences (nucleotide, exon, gene, pathway, exome).
These metrics are directly comparable between platforms and can be combined between samples to give “power
estimates” for an entire study. We estimate a local read depth of 13X is required to detect the alleles and genotype of
a heterozygous SNV 95% of the time, but only 3X for a homozygous SNV. At a mean on-target read depth of 20X,
commonly used for rare disease exome sequencing studies, we predict 5–15% of heterozygous and 1–4% of
homozygous SNVs in the targeted regions will be missed.
Conclusions: Non-reference alleles in the heterozygote state have a high chance of being missed when commonly
applied read coverage thresholds are used despite the widely held assumption that there is good polymorphism
detection at these coverage levels. Such alleles are likely to be of functional importance in population based studies of
rare diseases, somatic mutations in cancer and explaining the “missing heritability” of quantitative traits.
Background
Targeted capture and sequencing of human exons (exome-
seq) is an increasingly popular addition to genotyping
microarrays and a lower cost alternative to whole genome
sequencing for researchers investigating heritable traits
[1]. The complete human protein-coding exome com-
prises only 1% of the human genome, and it is typically in
what would be considered the easier fraction to sequence
and align uniquely to a reference genome. Most of the
causal disease variants identified to date have been in
protein-coding exonic sequence [2], and there are well
established experimental paradigms to explore the func-
tional consequences of amino acid changing variants. As
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the approach is sequence based, there is the potential to
ascertain all simple sequence variants within the targeted
regions in each member of a study cohort.
Exome-seq has been successfully applied to identify
causal variants in a number of Mendelian genetic disor-
ders [3-5]. These study designs often require only tiny
cohorts with little or no pedigree information, making
many diseases tractable to genetic study for the first time.
Exome-seq is also being used to study somatic muta-
tions in cancers [6] and has been proposed as a method
to study complex traits where the ability to detect rare
variants along with new variant discovery make it an
ideal complement to association studies [7,8]. Causal vari-
ants for complex diseases previously identified through
microarray-based association studies have been shown to
localize in or near exonic sequence [9], and human exomes
contain an excess of rare non-synonymous coding variants
that could explain some part of the missing heritability
problem [10].
© 2013 Meynert et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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For all re-sequencing projects (where there is a closely
related reference sequence that can be used for assem-
bly, rather than requiring de novo sequence assembly), the
total amount of usable sequence is considerably less than
the amount that comes off the sequencing machines. Two
standard analysis steps reduce the amount. First, reads
that cannot be uniquely mapped to the genome cannot
be used. A read may be unmappable because a) it con-
tains too many sequencing errors, b) it is relatively error
free but contains too many non-reference bases, c) it maps
to an insertion, deletion, or structural variant, or d) it
maps to multiple positions in the genome equally well.
Second, duplicate reads are removed. Duplication is gen-
erally defined as having identical position in the genome,
but may or may not include identical read sequence.
Removing duplicate reads minimises issues with PCR
amplification and improves the specificity of variant
calling [11].
Exome sequencing suffers from the additional problem
of off-target reads, those generated from the genomic
sample but outside the regions targeted for capture [12].
These reads can certainly be used for polymorphism dis-
covery, but they are unlikely to map to protein-coding
sequence or even regulatory features. After applying all
three of these reductions, the percentage of usable on-
target reads can be as low as 35% [3,4]. Read mapping also
demonstrates a bias towards the reference sequence: reads
that contain too many alternate alleles align with lower
scores to the reference genome than reads with only ref-
erence alleles [13]. As a consequence of heterogeneity in
target capture efficiency, amplification and themapping of
reads to the reference genome, usable reads are unevenly
distributed over the targeted regions.
There has rightly been a great deal of focus on accu-
rately measuring the specificity of single nucleotide vari-
ant (SNV) calls in next-generation sequence data (e.g.
[11]). But it is also hugely important for study design and
the interpretation of results to understand the sensitivity
attained. How many SNVs are likely to have been missed
and where are they most likely to be located? Ajay and
colleagues [14] have gone some way to addressing this
problem by showing that at the commonly used thresh-
old of 30X coverage, 30% of protein coding regions have
insufficient read depth to confidently call genotypes. We
set out to extend this observation to a wide range of
read depths and compare the consistency of SNV calling
sensitivity between genomic regions.
To measure the sensitivity of SNV detection we have
applied down-sampling to deeply sequenced exomes and
asked how well the down-sampled alignments perform
at calling known SNVs that are both present in the
full alignment and genotyped by the HapMap Phase III
project [15]. This approach provides us with a gold-
standard set of SNVs that can be generated for any deeply
sequenced human target and allows cross-comparison of
platforms and laboratories without the need to repeat-
edly and deeply sequence a known reference. With this
gold-standard we have investigated the relationship of
SNV detection sensitivity to both average coverage over
the entire targeted exome and per-nucleotide coverage for
each variant.
Calibrating SNV detection sensitivity with per-
nucleotide coverage allows us to estimate how many
genuine SNVs may have been missed in a specific tar-
geted region and evaluate whether an exon or gene can be
considered thoroughly screened for SNVs in an individ-
ual. It also provides the potential to correct the observed
rate of polymorphism for biases in coverage between
genomic regions. This is crucial for the robust applica-
tion of population based measures of mutation, selection
and demography [16] that are becoming increasingly
important for the functional interpretation of non-coding
regulatory sequences [17].
The relationship between mean on-target read depth
and SNV sensitivity is important for study design where
a researcher must generally decide a priori how to handle
the trade-off between the number of individuals to study
and the depth at which to sequence them. To explore this
relationship we have collected exome sequence data, gen-
erated at unusually deep coverage, from separate laborato-
ries and utilising four different capture technologies. Our
principal aim here is not a comprehensive comparison of
competing exome capture technologies, such studies have
been published elsewhere [12,18-20], rather to understand
real world variances in target capture efficiency and uni-
formity. In the case of rare genetic disorders, the focus
is on how much sequencing is required to confidently
identify the majority of variants in the targeted regions
of an individual. We address the problem in the con-
text of both autosomal dominant and recessive disorders,
in which both heterozygous and homozygous mutations
may be implicated. In this work, we asked what level of
mean on-target read depth is required to accurately iden-
tify a given percentage of SNVs, where accuracy includes
position, alleles, and genotype.
Results and discussion
Simulating shallower sequencing
Thirty capture-targeted and sequenced human exomes,
encompassing two different laboratories and four dif-
ferent capture methods, were aligned to the refer-
ence genome using a standard protocol (see Methods,
Additional file 1: Table S1a,b). Twelve of these exomes are
part of an ongoing disease study, subsequently denoted
HW samples and the remaining 18 have been previously
published [1,5]. Of the previously published exomes, eight
were from individuals genotyped in the HapMap Phase
III project [15], (Additional file 1: Table S1a). The deep
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sequencing of these exomes enabled us to explore SNV
detection sensitivity by random down-sampling of reads
to simulate shallower sequencing. The down-sampled
alignments were randomly generated from the original
“full alignments” by including each read with a given prob-
ability (see Methods). As the exomes were captured using
a mixture of technologies by different laboratories, we
defined a common set of targets using CCDS [21].
SNV detection sensitivity as a function of read depth at a
polymorphic site
We called SNVs on all full and down-sampled alignments
using the GenomeAnalysis Toolkit (GATK) UnifiedGeno-
typer tool [11]. SNV calls were considered “true” if they
were represented (matching position and alleles) in the
set of polymorphic sites genotyped by the HapMap Phase
III project [15], located within the CCDS target regions,
and found in the full alignment for a given exome. The
cross-reference to known polymorphic sites allowed us
to include all SNV calls with a reasonable assumption of
accuracy that did not require filtering on the variant qual-
ity score or read depth. We validated our true set of SNV
calls for the eight HapMap exomes against the genotype
calls from the HapMap project [15] and found concor-
dance of 99.7 ± 0.1% for heterozygous SNVs and 99.1 ±
0.4% for homozygous SNVs.
SNV calls from the down-sampled alignments were
labelled “positive” if they met the same criteria as the
“true” SNV calls in the full alignments. We classified pos-
itive SNV calls according to whether or not they were
observed in the set of true SNV calls for the exome, and
whether or not the genotype of the calls matched. Pos-
itive SNV calls observed in the true set with matching
genotype were labelled true positives; those with mis-
matched genotype were labelled partial true positives.
Partial true positives can be of two types. The more com-
mon heterozygous true–homozygous positive SNV calls
occur when the down-sampled alignment has too few
reference allele reads to call the position heterozygous.
Homozygous true–heterozygous positive SNV calls are
the opposite case: when the down-sampled alignment has
sampled by chance enough reads with the reference allele
to call the position heterozygous, but given all the reads at
that position, the variant calling algorithm identifies these
as sequencing errors.
We measured sensitivity as a function of read depth
at each true SNV site (Figure 1, Additional file 2) as
described in Methods. Within the subset of CCDS tar-
geted by all four capture methods, 95% detection sensitiv-
ity was reached for homozygous SNVs at depths of ≥ 3X
and for heterozygous SNVs at depths of ≥ 13X. At posi-
tions with 10X read depth, only 90 ± 3% of heterozygous
SNVs are correctly detected whereas the remaining 7–
13% are typically called as non-polymorphic (Additional
Figure 1 SNV detection sensitivity as a function of depth at the
polymorphic site. Sensitivity of at least 95% is reached at depths of
3X for homozygous SNVs and 13X for heterozygous SNVs. Raw data
for these curves is available (Additional file 2).
file 1: Table S2). At these lower read depths it was also
common to observe partial true positive calls where het-
erozygous sites were miscalled as homozygous for the
non-reference allele. Our results show that empirical sen-
sitivity is substantially worse than that predicted from the
naive expectation of sampling from a binomial (Additional
file 1: Figure S2).
Sensitivity in polymorphic sites used as our true set
was higher than those identified in the full alignments
within the shared CCDS targets and not occurring in
the HapMap Phase III set (Additional file 1: Figure S1a).
This is likely due to the higher rate of low quality vari-
ants in the latter set. The application of a commonly
used Phred-scaled quality threshold of 30, correspond-
ing to an expected 0.1% false call rate, to both the known
and novel variants makes the two curves indistinguish-
able (not shown). The rate of missed heterozygote calls at
low read depth is therefore not an unusual feature of sites
genotyped by the HapMap project, and polymorphisms
are generally called in the full alignments with high pre-
cision. No significant difference was observed between
sensitivity of detecting homozygous SNVs in regions con-
sidered difficult (see Methods) to capture, sequence, and
map, and SNVs in general; however, heterozygous SNVs
in these regions were more easily detected at lower
depths (Additional file 1: Figure S1b). This counterintu-
itive observation may relate to the typically higher G+C
content of difficult regions (see below) and a conse-
quent reduced bias for capturing the reference allele. The
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number of HapMap Phase III SNV sites in these diffi-
cult regions was relatively small (on average 283 ± 117
across the full CCDS target, compared to 1132 ± 419
for HapMap Phase III sites in the shared CCDS target),
and none had read depth over 9X. There was no differ-
ence between the four capture methods in measured SNV
detection sensitivity given the depth at a polymorphic
site (Additional file 1: Figure S1c). Per-site on-target read
depth is thus a good predictor of polymorphism detec-
tion sensitivity across target regions, between capture
platforms and amongst laboratories. Using these results,
sensitivity can be calculated across a gene or target set of
interest to identify regions which are under-covered for
the purpose of variant detection (e.g. Figure 2). Software
to achieve this is provided (Additional file 3).
SNV detection sensitivity as a function of mean on-target
read depth
Using the sensitivity curves described in Figure 1, we
calculated the total potential detection sensitivity of tar-
geted regions for the 30 exomes. Because of differences
in target probe design, we used the CCDS exon defi-
nitions (see Methods). Total detection sensitivity for an
exome was defined as the sum across all positions in the
target regions of the depth at that position multiplied
by the mean SNV detection sensitivity for that depth,
calculated separately for both heterozygous and homozy-
gous SNVs (Figure 3). We estimated the mean on-target
read depth required for achieving varying levels of total
potential recall on the CCDS target set for the four cap-
ture methods separately and together (Table 1). Using the
complete set of CCDS target regions highlights the differ-
ences in probe design between the four capture methods
(Additional file 1: Figure S3a), while examining the subset
of regions covered by at least one exome for each method
individually (see Methods) gives a very similar result to
the set of regions targeted by all four methods (Additional
file 1: Figure S3b).
Different capture technologies have varying levels of tar-
get uniformity and efficiency. Exomes captured by the
two custom array-based methods (HapMap and Kabuki)
had the most uniform coverage, followed by the HW-
Nimblegen exomes (Additional file 1: Figure S4). Other
researchers have also observed higher uniformity of cov-
erage in exomes captured by Nimblegen array kits com-
pared to Agilent kits [18,19,22]. This difference is likely
due in part to the different probe design strategies taken
by Nimblegen and Agilent, as Nimblegen’s SeqCap EZ
solution-based kit also generates more uniform coverage
than Agilent kits [12]. The lower uniformity of read depth
in the HW-Agilent exomes explains the higher levels of
mean on-target read depth required to achieve similar
levels of SNV detection sensitivity.
Replicate samples
Two of the HW samples were captured once by each of the
two capture methods (Agilent and Nimblegen). We com-
pared the SNV calls in the subset of of CCDS targeted by
all four capture methods from the full alignments of the
replicates. For SNVs in the HapMap Phase III set where
genotypes were called in both samples, concordance
was >99% for both replicate pairs and for both heterozy-
gous and homozygous genotypes. For novel sites, con-
cordance was >98% for heterozygous sites and >95% for
homozygous sites. The main difference between the repli-
cates was in the number of novel SNVs called from the
HW-Agilent samples that did not appear in the set of
SNVs called from the HW-Nimblegen samples. 66% of
novel SNVs called from HW10 (Agilent) were not called
from HW03 (Nimblegen); likewise 54% from HW11 (Agi-
lent) were not called from HW05 (Nimblegen). This was
not due to lack of read depth in the Nimblegen samples at
these sites (Additional file 1: Figure S5); in fact, the Nim-
blegen samples had greater depth at these sites on average
(one-sided Wilcox rank sum test p < 2 × 10−16 for both
replicate pairs). Sample HW07, which was captured and
Figure 2 SNV detection sensitivity across the example gene FERMT3 for the exome HW07. Grey vertical lines denote exon boundaries.
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Figure 3 SNV detection sensitivity as a function of mean on-target read depth.Mean on-target read depth is calculated using bases aligned to
the set of target regions covered by all exome capture platforms.
sequenced at the same time as samples HW10 and HW11,
also has roughly 2.5X as many novel heterozygous variant
calls as the other 25 samples (Additional file 1: Table S1c).
This appears to be an experimental batch effect.
Characteristics of “difficult” target regions
The target regions were split into maximum 100bp non-
overlapping tiles and classified as “difficult” or “easy” to
capture, sequence andmap for each exome (seeMethods).
Consistent with earlier reports [3,12,20,23], tiles classi-
fied as difficult in at least five of the sequenced exomes
had higher G+C content compared to those classified as
easy in at least five (one-sided Wilcox rank sum test p <
2× 10−16; Additional file 1: Figure S6). Difficult tiles were
more likely to be annotated with simple repeats than easy
tiles (χ2 test p < 2 × 10−16). Bainbridge and colleagues
also noted that low complexity regions were less likely
to be well-covered [23]. This is likely due to a combina-
tion of the difficulty in uniquely mapping reads to these
regions, and in designing probes for them. Across all 30
exomes, on average 63± 21% of difficult target region tiles
were shared between any given pair of exomes, implicat-
ing technology-agnostic issues such as read mappability.
There was more variation among easy target region tiles,
with only 36 ± 22% of such tiles shared on average across
all exomes. However, exomes captured by the same or
similar method were more likely to have difficulty with
certain target tiles (Additional file 1: Figure S7).
Conclusions
We used down-sampling of deeply sequenced exomes
along with cross-referencing to known SNV sites to mea-
sure how read depth influences SNV detection sensitivity.
The considerable per-nucleotide sequence depth required
to achieve 95% sensitivity for heterozygous SNVs high-
lights a substantial missing-data problem that is often
overlooked in next-generation sequence analysis. For
example, Ng and colleagues [5] used 8X coverage of a
site as a threshold to call polymorphisms, but at this cov-
erage we find that 16% of heterozygous polymorphisms
Table 1 Mean on-target read depth required for varying SNV detection sensitivity in targeted regions
Total detection sensitivity
80% 90% 95%
Source Het Hom Het Hom Het Hom
HapMap 11.1± 0.9 5.3± 1.2 17.2± 0.9 8.3± 1.1 19.7± 0.9 9.0± 1.1
Kabuki 14.9± 1.9 7.6± 1.6 27.7± 6.1 12.2± 2.0 34.5± 8.4 18.0± 4.9
HW - Nimblegen 15.9± 2.5 9.3± 1.6 24.5± 1.9 9.3± 1.6 31.1± 2.7 15.9± 2.5
HW - Agilent 18.4± 1.6 9.5± 0.8 36.5± 3.5 15.2± 2.8 45.6± 4.2 21.7± 2.8
HW = Human Genetics Unit/Wellcome Trust Sanger Institute.
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are missed by the standard genotype calling strategies
(Figure 1, Additional file 1: Table S2). Raising the coverage
threshold to 10X (10%missing heterozygote calls) reduces
the expected number of missing variant calls, but they
remain substantial.
The problem of missing heterozygote SNVs stems from
the stochastic and possibly also biased sampling of alle-
les by sequence reads [20]. If the reference genome allele
is more sampled, non-reference alleles may be either
not represented or at an insufficient frequency to pro-
duce a confident (exceeding a quality score threshold)
genotype call. In contrast, if the non-reference allele
is more abundantly sampled, information in the ref-
erence sequence is used to bolster the confidence of
a reference allele call. Consequently the missing vari-
ant calls are specifically biased to non-reference alleles
in the heterozygous state, precisely the alleles that are
most likely to be of interest in population based (non-
consanguineous) studies of rare disease and somatic can-
cer mutations.
We are not advocating the use of an excessively deep
threshold to call polymorphisms; it makes sense to max-
imally use the available sequence information in an
attempt to call variants even in regions of low sequence
coverage. However it is important to quantify how likely
a polymorphism is to remain undetected. This quantifi-
cation can be achieved with the down-sampled align-
ment based calibrated data (Figure 1, Additional file 1:
Table S2) that we have shown is portable between
laboratories, platforms and agnostic to sequence qual-
ity score filtering. This will allow genes of interest to
be scored according how thoroughly they have been
screened for variants and identify sub-regions that may
warrant follow-up targeted sequencing to improve cover-
age.
We have demonstrated that mean on-target read depth
of 17–37X is required to identify 90% of heterozygous
SNVs in the targeted regions for a given capture method,
depending primarily on uniformity of read coverage. Het-
erogeneity in read coverage is inherent in all sequencing
technologies but it is particularly pronounced in target
capture approaches. This unevenness of coverage is the
main reason it requires every target nucleotide to be
sequenced dozens of times, to ensure sufficient coverage
over the difficult targets to achieve reasonable sensitivity.
Some exons are persistently difficult to capture for mul-
tiple methods. Our sensitivity estimates are based on the
set of SNVs that can be discovered in the alignments with
the maximum available data, so they naturally exclude
some real SNVs in these difficult target regions. It is pos-
sible that a second round of capture, focusing on difficult
exons, such as that carried out by Ng and colleagues [1],
may be necessary in rare disease projects if no probable
candidates are found.
Rates of polymorphism and allele frequencies within
regions of the genome or categories of annotated sites can
be used to help measure aspects of demography, selec-
tion and mutation [16]. But if there is a systematic bias
in polymorphism detection sensitivity between regions
of a genome being compared (for example a category of
sequence biased towards difficult to capture sequence),
these important measures will be distorted and under-
mined. Again using the single nucleotide resolution cali-
brated data (Additional file 1: Table S2) the average variant
detection sensitivity of genomic regions or categories of
sites could be compared and if necessary a correction
applied in the case that sensitivity is not balanced between
comparators.
Despite the missing polymorphism problem, from an
analysis perspective themost immediate challenge is more
likely to be too many probable candidates, and prioriti-
sation of candidate causal variations and genes will be
required. The rare genetic disorders that have been inves-
tigated using exome-seq so far have proved amenable to
stringent filtering of known variation followed by dam-
age prediction. As technology advances and sequencing
becomes cheaper, researchers will need new methods to
handle larger data sets and the inevitable inclusion of pre-
viously observed variants as disease or trait contributing
candidates.
With rapid advances in sequencing technology there
will soon come a cross-over point where whole genome
sequencing is cheaper than exome-seq. The methods and
missing variant-call problem described here apply not
only to exome-seq but also to whole genome sequenc-
ing. The capturing of smaller target sets but across many
more patients, for example to validate a substantial genetic
effect contributed by multiple rare variants at a locus
[24], is likely to be common in the future. Estimating the
likelihood of missing heterozygous SNVs in a sequenced
sample will be an integral part of analyzing the results of
all such studies.
Methods
Exome capture and sequencing
Six of the HW exomes were captured using a Roche
NimbleGen 2.1M array kit targeting exonic sequence as
described by CCDS [21], and the other six with the Agi-
lent SureSelect All Exon 38M solution kit targeting exonic
sequence annotated by the GENCODE Consortium [25].
Paired-end reads of 54 bp were generated on the Illumina
GAII platform.
Two individuals were captured twice, once with each
technology. Exomes HW03 and HW10 were sampled
from the same individual; likewise exomes HW05 and
HW11.
FASTQ reads for 8 HapMap exomes [1] were obtained
from the NCBI Sequence Read Archive [26]. These
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exomes were captured with two custom Agilent 244K
microarrays and single-end 76 bp reads generated on the
Illumina GAII platform. FASTQ reads for 10 Kabuki case
exomes [5] were obtained from the NCBI dbGAP resource
[27]. These exomes were captured on a custom Agilent
1M aCGH array and a mix of single- and paired-end 76
bp reads generated on the Illumina GAII platform. See
Additional file 1: Table S1 for accessions. Additional file 1:
Table S3 summarises sequence and capture technology
used to generate each of the four data sets: HapMap,
Kabuki, HW-Nimblegen and HW-Agilent.
Ethical approval and consent
Informed consent was obtained from the families of all
patients involved in the study HW data set. The study was
approved by the Multi-centre Research Ethics Committee
for Scotland (04:MRE00/19).
Alignments
Reads for all 30 exomes were aligned to the hg19/GRCh37
assembly of the human genome reference sequence with
BWA 0.5.9 [28]. Duplicate reads were removed using the
MarkDuplicates function of Picard 1.79 (http://picard.
sourceforge.net). Reads were re-aligned around indels and
quality scores re-calibrated using the Genome Analysis
Toolkit (GATK), release 2.2–8-gec077cd [29]. Full param-
eters are given in the Additional file 1. We randomly
down-sampled reads from exome alignments using Picard
DownsampleSam, which maintains read pair information.
The probability of sampling each read varied from 0.1 to
0.9 at intervals of 0.1.
Target regions
We defined a set of target regions using the 25 October
2012 CCDS exon definitions [21]. Overlapping coordi-
nates from CCDS genes with status “Public” were merged
so that every position was represented only once. Read
depth at a particular base in a target region was defined as
the total number of reads overlapping the position. This
included reads which aligned with a gap to the position.
The target regions were split into maximally 100 bp non-
overlapping tiles for further analysis, with small tiles at
target region edges. We defined the set of targeted regions
for each capture method as the set of tiles which were
covered by at least one read in at least one exome for
that method. The intersection of the four target sets thus
defined was used to compare sensitivity across capture
methods.
We considered a base well-covered if it had a read depth
of at least 10, and a target region tile as well-covered
if at least 90% of its bases were well-covered. “Difficult”
target region tiles had no well-covered bases in the full
alignments. “Easy” target regions were well-covered in the
downsampled alignments with read inclusion probability
0.1.
SRS086455 from the Kabuki exomes and HW06 from
the HW-Nimblegen exomes each had considerably fewer
well-covered targets than the other exomes from their
respective sources, indicating partial capture failure.
These two samples were excluded from all summary
statistics and figures.
Variants
Variants were called on the full and down-sampled align-
ments using Samtools 0.1.12a [30]. An independent set of
variant calls was made using the Genome Analysis Toolkit
(GATK) UnifiedGenotyper tool, release 2.2–8-gec077cd
[11] (full parameters in Additional file 1). We obtained
HapMap Phase III sites and genotypes from the project
FTP site [15]. Variants from this set were mapped by
position and alleles to called variants in the full and down-
sampled alignments. Genotypes were mapped for the 8
HapMap exomes.
Sensitivity by depth at position
Sensitivity for a given genotype g (heterozygous or
homozygous) and read depth d was calculated as:
TP
TP + PTP + FN
where TP and PTP were the number of correctly posi-
tioned SNV calls of genotype g at read depth ≤ d with
correct or incorrect genotype respectively and FN was the
number of SNV calls of genotype g made in the full align-
ment where there was no corresponding call made in any
down-sampled alignments with read depth ≤ d at that
position. See Additional file 1 for a worked example.
Availability of supporting data
Reads for the HW exomes are available upon request.
Additional files
Additional file 1: Supplementary information. Supplementary
information, figures, and tables.
Additional file 2: recall.tsv. Tab-delimited text file containing empirical
sensitivity estimates for read depths up to 100X.
Additional file 3: depth_and_recall.r. R scripts for applying empirical
sensitivity curve to exome alignment data.
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